Unanticipated Increases in Hepatic Steatosis among HIV Patients Receiving MR Antagonist Eplerenone for NAFLD.


BACKGROUND & AIMS Nonalcoholic fatty liver disease is common in HIV, but there are no approved therapies. The aim of this open-label proof-of-concept study was to determine the effect of the mineralocorticoid receptor antagonist eplerenone on hepatic fat in HIV-infected patients with hepatic fat ≥ 5% by magnetic resonance spectroscopy. METHODS Five… (More)
DOI: 10.1111/liv.13734


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics